文献速递外周动脉疾病

早发外周动脉疾病晚期股腘病变旁路与腔内干预结局比较

Outcomes of bypass and endovascular interventions for advanced femoropopliteal disease in patients with premature peripheral artery disease.
PubMed 文献 · J Vasc Surg · 2021-06-06

基于VQI 2003–2019年数据,对2538例早发PAD(≤50岁)行孤立股腘血运重建者分析,并按TASC C/D病变行1:1倾向评分匹配。匹配后各466例,旁路组围术期并发症更高(12.0% vs 7.9%;

要点

  • 早发PAD晚期股腘病变,旁路1年再干预率低于腔内(17.0% vs 25.2%)。
  • 旁路围术期并发症高于腔内(12.0% vs 7.9%),大截肢与死亡率无差异。
  • 大隐静脉旁路与腔内比较,匹配后结局相似。

核心结论

  • 对早发PAD晚期股腘病变,旁路手术降低1年再干预率但增加围术期并发症和住院时间,大截肢与死亡率无差异。

研究设计与样本

  • 回顾性队列研究,纳入VQI股腘旁路与外周血管介入文件2003–2019年早发PAD(≤50岁)行孤立股腘血运重建患者共2538例。
  • 对TASC C或D病变行旁路与腔内1:1倾向评分匹配,匹配后各466例,基线无显著差异。
  • 另对股腘旁路使用大隐静脉与孤立股腘腔内干预行倾向评分匹配比较。

主要发现

  • 匹配前腔内组糖尿病(68.9% vs 54.0%;P<.001)、冠心病(31.0% vs 23.0%;P<.001)、需透析肾衰竭(14.2% vs 7.2%;P<.001)、跛行(45.1% vs 36.6%;P<.001)比例高于旁路组。
  • 匹配后旁路组围术期并发症高于腔内组(12.0% vs 7.9%;P=.038),大截肢与死亡率无差异。
  • 1年时旁路组再干预率低于腔内组(17.0% vs 25.2%;P=.012),大截肢(7.7% vs 7.9%;P=.928)与死亡率(5.2% vs 5.2%;P=1.00)无差异。
  • 大隐静脉旁路与腔内干预倾向评分匹配后结局相似。

关键数值与推荐

  • 早发PAD定义为就诊时年龄≤50岁。
  • 分析病变为孤立股腘TASC C或D病变。
  • 主要结局为1年再干预、通畅性、大截肢和死亡率。

临床怎么用

  • 早发PAD晚期股腘病变选择旁路或腔内时,需权衡旁路更低再干预率与更高围术期并发症。
  • 医患沟通中可告知两种策略1年大截肢与死亡率无差异。
  • 大隐静脉旁路与腔内结局相似,决策需结合患者具体解剖与合并症。

局限性

  • 原文未报告局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Patients with premature peripheral artery disease (PAD), defined as age ≤50 years at presentation, have had poor outcomes with open and endovascular lower extremity revascularization. It is unclear whether either strategy is associated with better outcomes because comparative studies have been limited to case series in this patient population. The aim of the present study was to compare the outcomes of patients with premature PAD who had undergone bypass or endovascular revascularization for advanced femoropopliteal disease. Our hypothesis was that open bypass would provide superior long-term outcomes compared with endovascular intervention for patients with premature advanced femoropopliteal PAD. METHODS: All the patients with premature PAD who had undergone isolated femoropopliteal lower extremity revascularization and included in the Vascular Quality Initiative infrainguinal bypass and peripheral vascular intervention files were reviewed from 2003 through 2019. Propensity score matching (1:1) was performed between patients who had undergone femoropopliteal bypass and endovascular interventions for isolated femoropopliteal Trans-Atlantic Classification System C or D lesions. The 1-year outcomes, including reintervention, patency, major amputation, and mortality, were analyzed. RESULTS: Of the 2538 included patients, 902 had undergone isolated femoropopliteal endovascular intervention and 1636 had undergone femoropopliteal bypass. The endovascular intervention group were more likely to have diabetes (68.9% vs 54.0%; P < .001), coronary artery disease (31.0% vs 23.0%; P < .001), renal failure requiring dialysis (14.2% vs 7.2%; P < .001), and claudication (45.1% vs 36.6%; P < .001) compared with the bypass group. After propensity score matching, 466 patients were in each group with no significant differences in the baseline characteristics. Perioperative morbidity was higher with femoropopliteal bypass compared with endovascular intervention (12.0% vs 7.9%; P = .038); however, the rates of major amputation and mortality were not different. At 1 year, patients who had undergone femoropopliteal bypass were less likely to require reintervention (17.0% vs 25.2%; P = .012). However, no differences were found in major amputation (7.7% vs 7.9%; P = .928) or mortality (5.2% vs 5.2%; P = 1.00). Propensity score matching was also performed between femoropopliteal bypass with the great saphenous vein and isolated femoropopliteal endovascular interventions, and the outcomes were similar. CONCLUSIONS: For patients with premature PAD and advanced femoropopliteal disease, bypass surgery decreased the reintervention rate at 1 year but was associated with increased perioperative morbidity and hospital length of stay compared with endovascular therapy. No differences were found in major amputation or mortality between the two strategies.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Kim TI, Zhang Y, Cardella JA, et al. Outcomes of bypass and endovascular interventions for advanced femoropopliteal disease in patients with premature peripheral artery disease. J Vasc Surg. 2021. PMID: 34090986. doi:10.1016/j.jvs.2021.05.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。